BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
Active, not recruiting · NCT02805023 · Registry updated 2025-06-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) | Arterial Occlusive Diseases, Chronic Disease, Chronic Limb-Threatening Ischemia, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, ischemic disease, peripheral arterial disease, peripheral vascular disease, vascular disorder | Active, not recruiting | Phase 1 / Phase 2 | 2025-06-06 | NCT02805023 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioGenCell Ltd. | 1 |
| Laniado Hospital | 2 |
| Rabin Medical Center | 33 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Johns Hopkins Hospital | Baltimore | United States | 135 |
| Laniado Hospital | Netanya | Israel | 1 |
| Rambam Health Care Campus | Haifa | Israel | 12 |
| University of San Francisco | San Francisco | United States | 2 |
| Yale University School of Medicine | New Haven | United States | 1 |